Log In
Print this Print this

Quillivant XR, methylphenidate

  Manage Alerts
Collapse Summary General Information
Company Tris Pharma Inc.
DescriptionOnce-daily, extended-release liquid methylphenidate developed using OralXRplus technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationAttention deficit hyperactivity disorder (ADHD)
Indication DetailsTreat attention deficit hyperactivity disorder (ADHD)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today